ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Axsome Therapeutics (AXSM)
Axsome Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$144.06▼ -0.68%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Axsome Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Axsome Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Axsome Therapeutics a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $131.97 and $156.01; in 9 out of 10, between $113.77 and $180.96. Estimated annual volatility is 45%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $9.7B
- 52-week high
- $260.19
- 52-week low
- $123.50
- Revenue (12 months)
- $777M
- Revenue growth (YoY)
- +65.6%
- Gross margin
- 92.6%
- Operating margin
- -26.5%
- Net margin
- -28.7%
- Return on equity
- -245.1%
- Free cash flow (12 months)
- $-4.6M
- Beta
- 0.71
What this means
ATLAS does not publish a fair value for AXSM right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks AXSM has traded between $123.50 and $260.19. Today it is 44.6% below that high and 17% above its low.
On the business: revenue grew 65.6% year over year; net margin is 28.7%.
Its beta is 0.71: it tends to move less than the market.
About the company
Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.
Want to see everything about Axsome Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Axsome Therapeutics do?
Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.
What is the chance AXSM goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, AXSM ends the month between $131.97 and $156.01.
How big is Axsome Therapeutics and what is its P/E ratio?
Axsome Therapeutics's market capitalization is $9.7B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is AXSM?
ATLAS estimates annual volatility at 45%. In a typical month, half of the outcomes end between $131.97 and $156.01.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer